VALNEVA SE EO -_15
Commented by André Will-Laudien on September 15th, 2022 | 13:35 CEST
Fighting Cancer: BioNTech, Defence Therapeutics, Valneva, MorphoSys - Which biotech stock is ahead in Biden's Moonshot?
Since the original launch of the Cancer Moonshot in 2016, the US cancer community has made measurable progress toward three ambitious goals. Namely, accelerating the scientific discovery of cancer, fostering greater collaboration, and improving cancer data sharing. In early 2022, President Biden announced a relaunch of the Cancer Moonshot and named new goals: To cut the cancer death rate in half within 25 years and significantly improve the lives of people with cancer. The initiative is just getting a new lease on life in the United States. Some biotech shares could make significant gains in this environment.
Read
Commented by Juliane Zielonka on August 18th, 2022 | 13:50 CEST
Apple, Tocvan Ventures, Valneva - More returns through innovation or risk hedging?
Innovations are hailed as market drivers. The more innovative a company is, the more likely it is to stay ahead of the competition. But this requires loyal customers who also support these innovations. And Apple has just such a customer base, setting a good example that loyalty must be rewarded for innovation. In contrast, pharmaceutical company Valneva has the challenge of exposure to different development cycles in the healthcare market. If only because of the duration of clinical studies, which rightly have to go well before a new product comes onto the market. This time, nature lovers could benefit. Those who find all this too volatile and unpredictable should once again turn to commodities as a hedge. With Tocvan Ventures, a candidate is in the running that looks very closely at optimizing the costs of its operations - to the benefit of investors.
Read
Commented by Armin Schulz on August 9th, 2022 | 13:45 CEST
BioNTech, Defence Therapeutics, Valneva - Will biotech stocks continue to rally in the fall?
The NASDAQ Biotechnology Index formed a double bottom in mid-June and has since rallied, breaking the downtrend. However, there is still over 32% potential to the past highs. The highs are due in part to the sales from the Corona Crisis, but even though currently the issue is not as present despite higher case numbers, that could change in the fall. The new Protection Against Infection Act provides for mask-wearing and further vaccinations. The profits from these sales are often invested in the development of new therapies, such as cancer research. These areas hold a lot of potential for rising share prices. We take a closer look at three biotech companies.
Read
Commented by Carsten Mainitz on July 28th, 2022 | 13:35 CEST
BioNTech, Defence Therapeutics, Valneva - Will the fall bring a new boost?
Officials expect the Corona pandemic to intensify sharply in the fall. Already, the number of cases is rising, as is the number of hospitalizations. To be better equipped against the currently prevalent Omicron variant, BioNTech/Pfizer have specifically adapted the Comirnaty vaccine to it. Valneva's recently approved vaccine also provides good protection against Omicron through a broader immune response to its inactivated vaccine. Also involved in vaccine development is the Canadian company Defence Therapeutics. It is currently attracting attention with its cancer-fighting developments and could become a real gem.
Read
Commented by Nico Popp on July 21st, 2022 | 11:24 CEST
Time is of the essence! Bavarian Nordic, XPhyto, Valneva
Resourceful investors always bet on corresponding stocks when new pathogens or disease patterns become known. BioNTech was one of the early movers in the case of COVID-19, but so were several other stocks that are now unknown again. Even for monkeypox, there have long been stocks that have profited - for example, the share of smallpox vaccine manufacturer Bavarian Nordic which recently rose sharply. We explain the hype around pharmaceutical stocks and outline where there could still be potential now.
Read
Commented by André Will-Laudien on July 18th, 2022 | 15:04 CEST
Fall is coming: BioNTech, Defence Therapeutics, CureVac, Valneva - Which biotech stock will surge again?
The summer of rising incidences is making its way, but the public has already shelved the pandemic measures and hospitals are filling up again. Even if no one wants to talk about it anymore, the fourth wave is coming! Worldwide, the race for suitable vaccines or treatment methods continues. Medicine is still relatively helpless as far as treating severe cases is concerned, and the subject of post-COVID is considered completely unexplored. We take another critical look at the landscape of biotech stocks.
Read
Commented by Fabian Lorenz on July 7th, 2022 | 14:33 CEST
A big surprise at BioNTech, and what are Valneva and NervGen doing?
Surprise at BioNTech: competitor CureVac sues the Mainz-based biotech company for alleged patent infringements. Specifically, the lawsuit concerns BioNTech's Corona vaccine, which is based on mRNA technology. CureVac founder Ingmar Hoerr, in turn, is considered the discoverer of this new vaccination technology. However, CureVac failed with the development of its own Corona vaccine. Valneva also had no luck with its Corona vaccine, but it seems to have an attractive product pipeline. Nevertheless, the euphoria over the entry of the US pharmaceutical group Pfizer has faded. The situation at NervGen is different: according to experts, NervGen could achieve its greatest success in decades with NVG-291 in the fight against Alzheimer's disease. Tomorrow, a capital increase is to be completed, and the share price will likely regain momentum.
Read
Commented by Stefan Feulner on July 5th, 2022 | 11:14 CEST
Strong signs at BioNTech and Defence Therapeutics, and Valneva closes the gap!
****Without question, the future belongs to biotechnology. The record-breaking development of vaccines, tests and drugs in the wake of the Corona pandemic, which broke out more than two years ago, showed how important this sector is for humanity. Biotechnology stocks are consolidating strongly despite being established as a critical future technology. The NASDAQ Biotech Index has lost about 40% since last summer, creating attractive entry opportunities for investors at a significantly reduced level.
Read
Commented by André Will-Laudien on June 30th, 2022 | 13:49 CEST
Biotech blockbusters: BioNTech, XPhyto Therapeutics, Valneva, CureVac - What to expect from these stocks?
Now that we have arrived in summer, the pandemic is weakening, and the media presence of the flu disease is also declining. That means less attention for pure-play vaccine makers, and now investors are asking how perhaps alternative money can be made. Is the pipeline of the protagonists strong enough to attract further investor capital, or will the whole industry go underground for the time being? We try our hand at being a truffle pig and dig beneath the surface. Which biotech stock has something up its sleeve?
Read
Commented by Fabian Lorenz on June 23rd, 2022 | 11:35 CEST
Takeover fantasy: +50% in Valneva shares, and what are BioNTech and Defence Therapeutics doing?
Tension is rising in the biotech sector as the takeover merry-go-round spins faster and has now hit Valneva. Pfizer's entry caused the stock to explode 50% in three trading days. Earlier, Pfizer had announced it would acquire migraine specialist Biohaven for USD 11.6 billion. Other pharmaceutical giants are also active: Halozyme wants to swallow Antares Pharma, a specialist in urology and endocrinology, for USD 960 million. The acquisition of Sierra Oncology is costing GlaxoSmithKline around USD 1.9 billion. Like Valneva, Defence Therapeutics is about to start important trials and could attract a major partner. A takeover of BioNTech is unlikely, but the flagship German biotech should also benefit from improved sentiment in the industry. The coming week should be operationally exciting for shareholders.
Read